, Volume 67, Issue 3, pp 457–474


A Review of its Use in the Management of Allergic Disorders
Adis Drug Evaluation



Rupatadine (Rupafin®, Rinialer®, Rupax®, Alergoliber®) is a selective oral histamine H1-receptor antagonist that has also been shown to have platelet-activating factor (PAF) antagonist activity in vitro. It is indicated for use in seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR) and chronic idiopathic urticaria (CIU) in patients aged ≥12 years.

Clinical trials show that rupatadine is an effective and generally well tolerated treatment for allergic rhinitis and CIU. It has a rapid onset of action and a prolonged duration of activity. Importantly, it has no significant effect on cognition, psychomotor function or the cardiovascular system. Once-daily rupatadine significantly improves allergic rhinitis symptoms in patients with SAR, PAR or persistent allergic rhinitis (PER) compared with placebo, and provides similar symptom control to that of loratadine, desloratadine, cetirizine or ebastine. In patients with CIU, longer-term use of rupatadine improves CIU symptoms to a greater extent than placebo. It is as well tolerated as other commonly used secondgeneration H1-receptor antagonists. Thus, the introduction of rupatadine extends the range of oral agents available for the treatment of allergic disorders, including allergic rhinitis and CIU.

Pharmacological Properties

Rupatadine shows a similar in vitro affinity for the H1 receptor to loratadine and terfenadine and, like loratadine, is selective for peripheral over central H1 receptors. The drug also demonstrates in vitro affinity for the PAF receptor. The antihistaminic activity and/or anti-inflammatory properties of rupatadine in in vitro studies and in animal models were similar to or greater than those of cetirizine, loratadine, desloratadine, levocabastine or terfenadine. However, unlike these H1 antihistamines, rupatadine also showed specific PAF antagonist activity in vitro and in animal models. In patients with SAR, rupatadine reduced nasal and non-nasal allergen-induced symptoms in an allergen challenge chamber study, and in healthy volunteers, inhibited histamine-induced flare responses. Rupatadine has no clinically relevant effects on the cardiovascular system (in a ‘thorough QT/QTc study’ the risk of QT/QTc prolongation was not increased at rupatadine dosages 10 times the usual dosage in healthy volunteers), cognitive function or psychomotor function.

Rupatadine is rapidly absorbed after oral administration; peak plasma concentrations are achieved within =1 hour and steady state within 3–5 days. Rupatadine is highly protein bound (98–99%) and is well distributed in tissues. It undergoes extensive presystemic hepatic metabolism, predominantly via the cytochrome P450 (CYP) isoenzyme CYP3A4 and is excreted mainly in the bile. Some metabolites are active (e.g. desloratadine and its hydroxylate metabolites) and may contribute to the overall efficacy and long duration of activity of rupatadine. Significant drug interactions between rupatadine and some agents that inhibit CYP3A4 activity occur (e.g. ketoconazole, erythromycin, grapefruit juice) and coadministration of the drug with these agents is not recommended.

Therapeutic Efficacy

Several randomised, placebo- and/or active comparator-controlled trials have shown that rupatadine is effective in improving symptoms in adult or adolescent patients with allergic rhinitis or CIU. In these trials, rupatadine was superior to placebo, showed similar efficacy to loratadine, desloratadine and cetirizine, and was at least as effective as ebastine in reducing allergic symptoms in patients with SAR. Likewise, the drug was also superior to placebo and as effective as loratadine, ebastine or cetirizine in patients with PAR. In patients with PER, rupatadine, but not cetirizine, was superior to placebo at improving allergic symptoms and health-related quality of life (HR-QOL) was improved to a similar extent with rupatadine or cetirizine and to a greater extent than with placebo. Improvements in HR-QOL with rupatadine that were evident in the 4-week double-blind, placebo-controlled phase of another study in patients with PER were maintained for up to 1 year in the open label extension phase. Rupatadine was superior to placebo in improving symptoms of urticaria in patients with CIU; this benefit was evident from the first week of treatment and was maintained throughout a 6-week trial.


Rupatadine was generally well tolerated in clinical trials. A pooled analysis of data from clinical trials indicated that the most common adverse events with rupatadine were somnolence (9.5%), headache (6.8%), fatigue (3.2%), asthenia (1.5%) and dry mouth (1.2%). The majority of adverse events were of mild or moderate severity and there was no significant difference in the overall incidence of adverse events between rupatadine, the active comparators or placebo. The good tolerability of rupatadine was confirmed in a 1-year tolerability study in which the most common adverse event was somnolence (5.8%); headache and dry mouth were each reported by 0.83% of patients.


  1. 1.
    Bousquet J, Van Cauwenberge P, Khaltaev N, et al. Allergic Rhinitis and its Impact on Asthma (ARIA): in collaboration with the World Health Organization. Allergy 2002; 57 (9): 841–55PubMedCrossRefGoogle Scholar
  2. 2.
    Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004 Sep; 114 (3): 465–74PubMedCrossRefGoogle Scholar
  3. 3.
    Tedeschi A, Airaghi L, Lorini M, et al. Chronic urticaria: a role for newer immunomodulatory drugs? Am J Clin Dermatol 2003; 4 (5): 297–305PubMedCrossRefGoogle Scholar
  4. 4.
    Kozel MM, Sabroe RA. Chronic urticaria: aetiology, management and current and future treatment options. Drugs 2004; 64 (22): 2515–36PubMedCrossRefGoogle Scholar
  5. 5.
    Berger WE. The safety and efficacy of desloratadine for the management of allergic disease. Drug Saf 2005; 28 (12): 1101–18PubMedCrossRefGoogle Scholar
  6. 6.
    Morgan MM, Khan DA, Nathan RA. Treatment for allergic rhinitis and chronic idiopathic urticaria: focus on oral antihistamines. Ann Pharmacother 2005 Dec; 39(12): 2056–64PubMedCrossRefGoogle Scholar
  7. 7.
    Picado C. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin Pharmacother 2006 Oct; 7 (14): 1989–2001PubMedCrossRefGoogle Scholar
  8. 8.
    van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000 Feb; 55 (2): 116–34PubMedCrossRefGoogle Scholar
  9. 9.
    Dykewicz MS, Fineman S, Skoner P, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998 Nov; 81 (5 Pt 2): 478–518PubMedCrossRefGoogle Scholar
  10. 10.
    Bousquet J, van Cauwenberge P, Aït Khaled N, et al. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN). Allergy 2006 Sep; 61 (9): 1086–96PubMedCrossRefGoogle Scholar
  11. 11.
    Zuberbier T, Bindslev-Jensen C, Canonica W, et al. EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy 2006 Mar; 61 (3): 321–31PubMedCrossRefGoogle Scholar
  12. 12.
    Broide DH. Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol 2001; 108 (2): S65–71PubMedCrossRefGoogle Scholar
  13. 13.
    Greiner AN, Meltzer EO. Pharmacologic rationale for treating allergic and nonallergic rhinitis. J Allergy Clin Immunol 2006 Nov; 118 (5): 985–96PubMedCrossRefGoogle Scholar
  14. 14.
    Hennino A, Bérard F, Guillot I, et al. Pathophysiology of urticaria. Clin Rev Allergy Immunol 2006 Feb; 30 (1): 3–11PubMedCrossRefGoogle Scholar
  15. 15.
    Horak F. Clinical advantages of dual activity in allergic rhinitis. Allergy 2000; 55 Suppl. 64: 34–9PubMedCrossRefGoogle Scholar
  16. 16.
    Merlos M, Giral M, Balsa D, et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther 1997 Jan; 280 (1): 114–21PubMedGoogle Scholar
  17. 17.
    García-Rafanell J. Rupatadine fumarate: antiallergic, histamine and PAF antagonist. Drugs Fut 1996 Oct; 21 (10): 1033–6Google Scholar
  18. 18.
    Uriach J, Cia SA. Rupafin 10mg comprimidos (rupatadina): resumen de las características del producto [online]. Available from URL: http://www.msc.es/profesional/farmacia/informaMedicamentos/doc/F_TecnicaNum64053.doc [Accessed 2004 Feb 3]
  19. 19.
    Merlos M, Balsa D, Giral M, et al. Inhibition of rat peritoneal mast cell exocytosis by rupatadine fumarate: a study with different secretagogues [abstract no. PA-95]. Methods Find Exp Clin Pharmacol 1997; 19 Suppl. A: 148Google Scholar
  20. 20.
    Giral M, Balsa D, Ferrando R, et al. CNS activity profile of rupatadine fumarate, a new dual receptor antagonist of platelet-activating factor and histamine [abstract no. P321]. Allergy 1998; 53 Suppl. 43: 131–2Google Scholar
  21. 21.
    Izquierdo I, Merlos M, Garcia-Rafanell J. Rupatadine, a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist: a review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today (Barc) 2003 Jun; 39(6): 451–68CrossRefGoogle Scholar
  22. 22.
    Queralt M, Brazis P, Merlos M, et al. Inhibitory effects of rupatadine on mast cell histamine release and skin wheal development induced by Ascaris suum in hypersensitive dogs. Drug Dev Res 1998; 44 (2–3): 49–55CrossRefGoogle Scholar
  23. 23.
    Queralt M, Brazis P, Merlos M, et al. In vitro inhibitory effect of rupatadine on histamine and TNF-α release from dispersed canine skin mast cells and the human mast cell line HMC-1. Inflamm Res 2000 Jul; 49(7): 355–60PubMedCrossRefGoogle Scholar
  24. 24.
    Queralt M, Merlos M, Giral M, et al. Dual effect of a new compound, rupatadine, on edema induced by platelet-activating factor and histamine in dogs: comparison with antihistamines and PAF antagonists. Drug Dev Res 1996; 39(1): 12–8CrossRefGoogle Scholar
  25. 25.
    Ferrando R, Giral M, Balsa D, et al. Protective effect of rupatadine fumarate in experimental conjunctivitis in guinea pigs [abstract no. P-21]. Methods Find Exp Clin Pharmacol 1996; 18 Suppl. B: 140Google Scholar
  26. 26.
    Merlos M, Giral M, Balsa D, et al. Rupatadine inhibits the eosinophil recruitment in BAL fluid of ovalbumin-sensitized guinea pigs [abstract no. 904]. J Allergy Clin Immunol 1998 Jan; 101 (Pt 2): S218Google Scholar
  27. 27.
    Stuebner P, Horak F, Zieglmayer R, et al. Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber. Ann Allergy Asthma Immunol 2006 Jan; 96 (1): 37–44PubMedCrossRefGoogle Scholar
  28. 28.
    Izquierdo I, Nieto C, Ramis J, et al. Pharmacokinetics and dose linearity of rupatadine fumarate in healthy volunteers [abstract no. PB-62]. Methods Find Exp Clin Pharmacol 1997; 19 Suppl. A: 189–203Google Scholar
  29. 29.
    Barrón S, Ramis I, Merlos M. Effect of rupatadine on lymphocyte cytokine production [abstract no. 1175]. Allergy Clin Immunol Int 2005; Suppl. 1: 427Google Scholar
  30. 30.
    Taglialatela M, Annunziato I. Evaluation of the cardiac safety of second-generation antihistamines. Allergy 2000; 55: 22–30PubMedCrossRefGoogle Scholar
  31. 31.
    Caballero R, Valenzuela C, Longobardo M, et al. Effects of rupatadine, a new dual antagonist of histamine and plateletactivating factor receptors, on human cardiac Kv1.5 channels. BrJ Pharmacol 1999 Nov; 128 (5): 1071–81CrossRefGoogle Scholar
  32. 32.
    Izquierdo I, Pérez I, Villa M. Lack of electrocardiographic effects of Rupatadine, new nonsedating selective histamine HI-receptor and PAF antagonist [abstract no. 637]. Allergy 2001; 56 Suppl. 68: 212Google Scholar
  33. 33.
    Ramis I, Giral M, Nieto C, et al. Lack of cardiotoxic effects of rupatadine in isolated Purkinje fibres and its relationship with rupatadine cardiac levels [abstract no. 947]. Allergy 2000; 55 Suppl. 63: 264Google Scholar
  34. 34.
    Giral M, Merlos M, Balsa D, et al. Effects of rupatadine on cardiovascular profile in rats and guinea pigs: comparison with other nonsedating antihistamines [abstract no. 110]. Allergy 1997; 52 Suppl. 37: 44Google Scholar
  35. 35.
    E14: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. ICH Harmonised Tripartite Guideline. Current Step 4 version. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2005 May 12 [online]. Available from URL: http://www.ich.org [Accessed 2006 Nov 16]
  36. 36.
    Donado E, Pérez I, García O, et al. Cardiac safety of rupatadine according to the new ICH guideline: a “thorough QT/QTc study” [abstract no. 760 plus poster]. The XXV Congress of the European Academy of Allergology and Clinical Immunology; 2006 Jun 10–14; ViennaGoogle Scholar
  37. 37.
    Barbanoj MJ, García-Gea C, Morte A, et al. Central and peripheral evaluation of rupatadine, a new antihistamine/plateletactivating factor antagonist, at different doses in healthy volunteers. Neuropsychobiology 2004; 50 (4): 311–21PubMedCrossRefGoogle Scholar
  38. 38.
    Vuurman E, Theunissen E, van Oers A. Lack of effects between rupatadine 10mg and placebo on actual driving performance of healthy volunteers. Human Psychopharmacol Clin Exp. In pressGoogle Scholar
  39. 39.
    Barbanoj MJ, García-Gea C, Antonijoan R, et al. Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers. Hum Psychopharmacol Clin Exp 2006 Jan; 21 (1): 13–26CrossRefGoogle Scholar
  40. 40.
    Solans A, Merlos M, Antonijoan R, et al. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin: a randomized, crossover, multiple-dose open study [abstract no. 410]. Allergy Clin Immunol Int 2005; Suppl. 1: 159Google Scholar
  41. 41.
    Izquierdo I, Paredes I, Lurigados C, et al. A dose ranging study of rupatadine fumarate in patients with seasonal allergic rhinitis [abstract no. 984]. Allergy 2000; 55 Suppl. 63: 275Google Scholar
  42. 42.
    Pérez I, De la Cruz G, Villa M, et al. Rupatadine in allergic rhinitis: pooled analysis of efficacy data [abstract no. 784]. Allergy 2002; 57 Suppl. 73: 245Google Scholar
  43. 43.
    Saint-Martin F, Dumur JP, Pérez I, et al. A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptorspecific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. J Investig Allergol Clin Immunol 2004; 14 (1): 34–40PubMedGoogle Scholar
  44. 44.
    Guadaño EM, Serra-Batlles J, Meseguer J, et al. Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study. Allergy 2004 Jul; 59(7): 766–71PubMedCrossRefGoogle Scholar
  45. 45.
    Martinez-Cócera C, De Molina M, Marti-Guadaño E, et al. Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study. J Investig Allergol Clin Immunol 2005; 15 (1): 22–9PubMedGoogle Scholar
  46. 46.
    Maspero J, Fantin S, Bisbal C, et al. A 12-week placebocontrolled study of rupatadine 10mg once daily comparative with cetirizine 10mg once daily, in the treatment of persistent allergic rhinitis [abstract no. 758 plus poster]. The XXV Congress of the European Academy of Allergology and Clinical Immunology; 2006 Jun 10–14; ViennaGoogle Scholar
  47. 47.
    Roger A, Arnáiz E, Valero A, et al. Rupatadine 10mg improves quality of life in long-term treatment of persistent allergic rhinitis [abstract no. 761 plus poster]. The XXV Congress of the European Academy of Allergology and Clinical Immunology; 2006 Jun 10–14; ViennaGoogle Scholar
  48. 48.
    Dubertret L, Zalupca L, Cristodoulo T, et al. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. Eur J Dermatol. In pressGoogle Scholar
  49. 49.
    Giménez-Arnau A, Pujol RM, Ianosi S, et al. Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicenter study. Allergy. In pressGoogle Scholar
  50. 50.
    Juniper EF, Thompson AK, Ferrie PJ, et al. Development and validation of the standardized Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ(S)) [abstract no. 273]. J Allergy Clin Immunol 1999; 103 (1 Pt 2): S71Google Scholar
  51. 51.
    Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 May; 19(3): 210–6PubMedCrossRefGoogle Scholar
  52. 52.
    El: The extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions. ICH Harmonised Tripartate Guideline. Current Step 4 version. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use [online]. Available from URL: http://www.ich.org/LOB/media/MEDIA435.pdf [Accessed 2006 Nov 23]
  53. 53.
    European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on the clinical development of medicinal products for the treatment of allergic rhinoconjunctivitis [online]. Available from URL: http://www.emea.eu.int/pdfs/human/ewp/245502en.pdf [Accessed 2006 Nov 23]
  54. 54.
    Valero A, Rivas P, Castillo JA, et al. One year safety data of rupatadine 10mg in patients with allergic rhinitis [abstract no. 759 plus poster]. The XXV Congress of the European Academy of Allergology and Clinical Immunology; 2006 Jun 10–14; ViennaGoogle Scholar
  55. 55.
    Salmun LM. Antihistamines in late-phase clinical development for allergic disease. Expert Opin Investig Drugs 2002 Feb; 11 (2): 259–73PubMedCrossRefGoogle Scholar
  56. 56.
    Baiardini I, Braido F, Cauglia S, et al. Sleep disturbances in allergic diseases. Allergy 2006 Nov; 61 (11): 1259–67PubMedCrossRefGoogle Scholar
  57. 57.
    Monroe E. Review of H1 antihistamines in the treatment of chronic idiopathic urticaria. Cutis 2005 Aug; 76 (2): 118–26PubMedGoogle Scholar
  58. 58.
    Salib RJ, Howarth PH. Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis. Drug Saf 2003; 26 (12): 863–93PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Wolters Kluwer Health / AdisMairangi Bay, AucklandNew Zealand
  2. 2.Wolters Kluwer HealthConshohockenUSA

Personalised recommendations